Seralutinib
Pulmonary Arterial Hypertension (PAH)
Key Facts
About Gossamer Bio
Gossamer Bio is a publicly traded biotech company dedicated to improving the lives of patients with rare diseases, primarily through the development of its lead candidate, seralutinib. The company's strategy leverages an inhaled delivery mechanism to target pulmonary hypertension directly in the lungs, aiming to overcome limitations of systemic therapies. With a seasoned leadership team experienced in drug development and company building, Gossamer is advancing its pivotal Phase 3 PROSERA study in PAH, positioning itself as a potential innovator in a high-need therapeutic area with significant market opportunity.
View full company profileAbout Gossamer Bio
Gossamer Bio is a publicly traded biotech company dedicated to improving the lives of patients with rare diseases, primarily through the development of its lead candidate, seralutinib. The company's strategy leverages an inhaled delivery mechanism to target pulmonary hypertension directly in the lungs, aiming to overcome limitations of systemic therapies. With a seasoned leadership team experienced in drug development and company building, Gossamer is advancing its pivotal Phase 3 PROSERA study in PAH, positioning itself as a potential innovator in a high-need therapeutic area with significant market opportunity.
View full company profileTherapeutic Areas
Other Pulmonary Arterial Hypertension (PAH) Drugs
| Drug | Company | Phase |
|---|---|---|
| ANPA-0073 | Structure Therapeutics | Preclinical |
| YUTREPIA™ (treprostinil) inhalation powder | Liquidia Corporation | Approved (Tentative) |
| LIQ861 (treprostinil) inhalation powder | Liquidia Corporation | Phase 3 |
| KER-012 | Keros Therapeutics | Phase 2 |
| CS1 | Cereno Scientific | Phase II |
| NTP42 | ATXA Therapeutics | Phase 1 |